Exelixis targeted for board challenge by Farallon Capital

The company's cancer-fighting drug cabozantinib is a blockbuster, but Farallon Capital Management said the company can unlock more value and return capital to shareholders.

Binski’s Bar opening in Camp Washington

One of St. Louis’ largest nonprofit organizations names new COO

Bahl & Gaynor’s Groenke still cycles most days

D.C. restaurants Causa, Rania snag Michelin stars

Phoenix-based U-Haul proposes massive self-storage facility in growing part of city

October bar/restaurant news: 15 openings, 10 closings, a dozen in development

Raleigh adding rooftop restaurant at The Dillon

Norcross lands food hall at South End project

Exelixis targeted for board challenge by Farallon Capital

Previous Celanese partners with pharmaceutical company to release new glaucoma treatment

Next Cell Therapy Manufacturing Center expands TMC space to boost acceleration of biotech products

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

New owner has strategy to make downtown Albany hotel stand out

NCR Corp. entering payments biz, buying payments processor JetPay

Homestead-based Deco Truss acquired by US LBM

Sweetgreen opens first RI restaurant in Cranston

Lower east side apartment building along The Hop tracks sells for twice its assessed value

2023 Health Care Leadership Awards: Audrea Caesar – UNC Health/UNC School of Medicine

MENU

FirstStar Group

More Stories

Avoid the December rush: Strategies for charitable giving

Previous Celanese partners with pharmaceutical company to release new glaucoma treatment

Next Cell Therapy Manufacturing Center expands TMC space to boost acceleration of biotech products

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories